486 related articles for article (PubMed ID: 18365595)
1. Foamy histiocytes in a patient with visceral leishmaniasis after treatment with liposomal amphotericin B.
Tavil B; Seçmeer G; Ozen H; Cengiz AB; Unal S; Gürgey A
Turk J Pediatr; 2008; 50(1):67-9. PubMed ID: 18365595
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
Lagler H; Matt U; Sillaber C; Winkler S; Graninger W
Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063
[TBL] [Abstract][Full Text] [Related]
3. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal gammopathy in human leishmaniasis.
Randi ML; Ruzzon E; Tezza F; Tezza F; Pacquola E; Fabris F
Neth J Med; 2006 Feb; 64(2):50-1. PubMed ID: 16517989
[TBL] [Abstract][Full Text] [Related]
5. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
Vigna E; De Vivo A; Gentile M; Morelli R; Lucia E; Mazzone C; Recchia AG; Vianelli N; Morabito F
Transpl Infect Dis; 2010 Oct; 12(5):428-31. PubMed ID: 20534035
[TBL] [Abstract][Full Text] [Related]
6. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.
Syriopoulou V; Daikos GL; Theodoridou M; Pavlopoulou I; Manolaki AG; Sereti E; Karamboula A; Papathanasiou D; Krikos X; Saroglou G
Clin Infect Dis; 2003 Mar; 36(5):560-6. PubMed ID: 12594635
[TBL] [Abstract][Full Text] [Related]
7. A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis.
Chattopadhyay A; Jafurulla M
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):7-12. PubMed ID: 22100811
[TBL] [Abstract][Full Text] [Related]
8. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
[TBL] [Abstract][Full Text] [Related]
9. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
[TBL] [Abstract][Full Text] [Related]
10. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
11. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
[TBL] [Abstract][Full Text] [Related]
12. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
[TBL] [Abstract][Full Text] [Related]
13. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
14. The hunt for an elusive source of pyrexia in a foreign worker.
Lew JW; Koh CK; Selvan VS; Shen E
Singapore Med J; 2007 Apr; 48(4):e111-3. PubMed ID: 17384865
[TBL] [Abstract][Full Text] [Related]
15. Visceral leishmaniasis after renal transplantation: report of 4 cases in northeastern Brazil.
Oliveira RA; Silva LS; Carvalho VP; Coutinho AF; Pinheiro FG; Lima CG; Leandro JE; Silva GB; Daher EF
Transpl Infect Dis; 2008 Oct; 10(5):364-8. PubMed ID: 18507750
[TBL] [Abstract][Full Text] [Related]
16. [Fever, pancytopenia, and splenomegaly 8 months after a trip to Majorca Island (Spain)].
Lübbert C; Opitz BM; Harms-Zwingenberger G; Nietsch HH
Med Klin (Munich); 2008 Jan; 103(1):29-35. PubMed ID: 18219460
[TBL] [Abstract][Full Text] [Related]
17. [Case report: the efficacy of amphotericin B in visceral leishmaniasis].
Güleç SG; Kizilyer Y; Karaman S; Erdem E; Urganci N
Turkiye Parazitol Derg; 2010; 34(2):73-5. PubMed ID: 20597048
[TBL] [Abstract][Full Text] [Related]
18. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
19. [A case of antimony resistant kala-azar cured with amphotericin B].
Chen SB; Yang CM; Zhang CJ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
[No Abstract] [Full Text] [Related]
20. [A patient with visceral leishmaniasis and acute renal failure in necrotizing glomerulonephritis].
Chaigne V; Knefati Y; Lafarge R; Bronner J; Mc Gregor B; Fouque D; Sabatier JC
Nephrologie; 2004; 25(5):179-83. PubMed ID: 15455792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
